Antibacterial activity of the new quinolone CI-960 (PD 127391) against clinical isolates at a major tertiary care center in Saudi Arabia.
The antibacterial activity of the new fluoroquinolone CI-960 (PD 127391) was evaluated against 1,162 clinical isolates and compared with other quinolones and various commonly used antibiotics. CI-960 was highly effective against members of Enterobacteriaceae inhibiting 626 of the 629 isolates at a less than or equal to 0.03 to 0.12 microgram/ml concentration. All the 305 isolates of Pseudomonas aeruginosa, Xanthomona maltophilia, and Acinetobacter were susceptible to CI-960. It was the only effective drug against 10 multi-resistant isolates of pseudomonads and Acinetobacter. All staphylococci, including methicillin-resistant Staphylococcus aureus, were inhibited by less than or equal to 0.03-0.5 microgram/ml of CI-960. Like other drugs of its class, it had little activity against enterococci.
Qadri
S M
SM
King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia.
Abo-Askar
H
H
Ueno
Y
Y
D000890:Anti-Infective Agents / Q000494:pharmacology*; D002939:Ciprofloxacin / Q000494:pharmacology; D016972:Enterobacter cloacae / Q000187:drug effects; D004755:Enterobacteriaceae / Q000187:drug effects; D024841:Fluoroquinolones; D006090:Gram-Negative Bacteria / Q000187:drug effects*; D006786:Hospitals, Urban; D007711:Klebsiella pneumoniae / Q000187:drug effects; D008826:Microbial Sensitivity Tests; D009643:Norfloxacin / Q000494:pharmacology; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D015363:Quinolones / Q000494:pharmacology*; D012529:Saudi Arabia
D000890:Anti-Infective Agents; D024841:Fluoroquinolones; D015363:Quinolones; D002939:Ciprofloxacin; C057477:clinafloxacin; D009643:Norfloxacin